Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 177 posts found.

GSK-Merck back new developing world cancer charity

September 14, 2011
Medical Communications Cancer, GSK, Merck & Co, Pink Ribbon-Red Ribbon, breast cancer, cervical cancer

GlaxoSmithKline and Merck are among the backers of a new charity that focuses on preventing female cancers in developing countries. …

News

NICE blames Faslodex rejection on uncertainties in AZ data

August 23, 2011
Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer

NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …

News

EMA extends Avastin breast cancer licence

July 1, 2011
Sales and Marketing avastin, breast cancer, metastatic breast cancer

The EMA has extended the breast cancer licence for Roche’s Avastin after initially restricting the drug’s use. The decision comes …

News

Eisai launches cancer drug Halaven in UK

April 20, 2011
Sales and Marketing Eisai, Halaven, breast cancer

Eisai’s sea sponge derived breast cancer drug Halaven has been launched in the UK following approval from European regulators a …

News

Eisai marine sponge derived cancer drug approved in Europe

March 23, 2011
Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate

Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …

News

Eisai prepares ground for Halaven’s European launch

March 7, 2011
Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin

Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …

News
Roche's Avastin (bevacizumab)

Avastin’s breast cancer use to continue in Europe

March 2, 2011
Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel

Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …

News
Roche's Avastin (bevacizumab)

NICE yes for Votrient, no to Avastin

February 23, 2011
Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …

News
Avastin (bevacizumab) packs

Study highlights Avastin heart failure risk

January 6, 2011
Research and Development, Sales and Marketing Roche, avastin, bevacizumab, breast cancer

A new study confirms that Roche’s Avastin is linked to a small but significant increased risk of heart failure in …

News

Roche to challenge FDA on Avastin

December 21, 2010
Sales and Marketing EMA, FDA, Roche, avastin, bevacizumab, breast cancer

Roche is set to challenge the decision by the FDA to remove a breast cancer indication from its blockbuster drug …

News

Novartis pulls Zometa submission after breast cancer failure

December 13, 2010
Research and Development, Sales and Marketing Novatis, Zometa, breast cancer, zoledronic

Novartis has pulled Zometa’s marketing application for an early breast cancer indication after the drug failed to meet its primary …

News

Hormone therapy drugs ‘increase heart disease risk’

December 10, 2010
Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen

Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …

News

Boehringer puts afatinib head-to-head with Herceptin

December 10, 2010
Research and Development BIBW 2992, Boehringer Ingelheim, Herceptin, Roche, Tovok, afatinib, breast cancer

Boehringer Ingelheim has set up a showdown between one of its pipeline oncology products and Roche’s Herceptin. It has started …

News
Avastin packs

NICE no for Avastin in breast cancer

December 8, 2010
Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta

NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …

News

FDA approves Eisai breast cancer drug Halaven

November 16, 2010
Sales and Marketing Cancer, Eisai, FDA, Halaven, Xeloda, breast cancer, eribulin mesylate, metastatic breast cancer

The FDA has approved Eisai’s advanced breast cancer drug Halaven for use in heavily pre-treated breast cancer patients. Halaven (eribulin …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025